Target Name: CD48
NCBI ID: G962
Review Report on CD48 Target / Biomarker Content of Review Report on CD48 Target / Biomarker
CD48
Other Name(s): CD48 antigen | BCM1 surface antigen | MEM-102 | signaling lymphocytic activation molecule 2 | Leukocyte antigen MEM-102 | CD48 molecule, transcript variant 1 | TCT.1 | CD48 variant 1 | CD48_HUMAN | OTTHUMP00000060268 | BCM1 | B-lymphocyte activation marker BLAST-1 | SLAM family member 2 | CD48 antigen (isoform 1) | mCD48 | SLAMF2 | Signaling lymphocytic activation molecule 2 | CD48 molecule | hCD48 | leukocyte antigen MEM-102 | BLAST | OTTHUMP00000025680 | CD48 antigen (B-cell membrane protein) | BLAST1

CD48 Antigen as a Drug Target and Biomarker: A Promising Approach in the Treatment of Chronic Diseases

CD48 antigen, also known as CD48 or CTLA-48, is a cell surface glycoprotein that is expressed in various tissues and organs, including blood cells, tissues, and organs. It plays a crucial role in the immune system, specifically in the regulation of T cell responses. CD48 has also been implicated in cancer progression and the regulation of immune responses. As a result, targeting CD48 antigen has become an attractive target for the development of new treatments for a variety of chronic diseases.

CD48 Antigen as a Drug Target

CD48 antigen has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key advantages of CD48 antigen as a drug target is its expression in multiple tissues and organs, which makes it more difficult to target. However, researchers have been able to develop small molecules that can specifically bind to CD48 antigen and inhibit its activity. These small molecules have been shown to be effective in preclinical studies in treating a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

One of the most promising small molecules that can bind to CD48 antigen is called CD48 antagonist 123. This compound was synthesized by researchers at the University of California, San Diego, and has been shown to be effective in preclinical studies against multiple diseases, including cancer. In particular, CD48 antagonist 123 has been shown to be effective in treating breast cancer, by inhibiting the activity of CD48 and increasing the sensitivity of cancer cells to chemotherapy.

Another small molecule that can bind to CD48 antigen is called CD48 inhibitor JNJ-752605. This compound was developed by Johnson & Johnson and has been shown to be effective in preclinical studies against multiple diseases, including cancer. In particular, CD48 inhibitor JNJ-752605 has been shown to be effective in treating breast cancer, by inhibiting the activity of CD48 and increasing the sensitivity of cancer cells to chemotherapy.

CD48 Antigen as a Biomarker

In addition to its potential as a drug target, CD48 antigen has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases. The ability of CD48 antigen to be expressed in multiple tissues and organs makes it an attractive biomarker for the diagnosis of cancer, autoimmune diseases, and neurodegenerative disorders.

One of the most promising applications of CD48 antigen as a biomarker is its ability to be used as a marker for cancer diagnosis. Cancer cells often have increased levels of CD48 antigen, making them more resistant to chemotherapy and other treatments. By measuring the level of CD48 antigen in cancer cells, researchers can determine the level of disease and monitor the effectiveness of different treatments.

Another application of CD48 antigen as a biomarker is its ability to be used as a marker for autoimmune diseases. Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. By measuring the level of CD48 antigen in the tissues and organs of patients with autoimmune diseases, researchers can determine the level of disease and monitor the effectiveness of different treatments.

CD48 Antigen as a Therapeutic

In addition to its potential as a biomarker and drug target, CD48 antigen has also been shown to be a potential therapeutic for the treatment of various diseases. The ability of CD48 antigen to be expressed in multiple tissues and organs makes it an attractive target for the development of new treatments.

One of the most promising applications of CD48 antigen as a therapeutic is its ability to be used in the treatment of cancer. Cancer cells often have increased levels of CD48 antigen, making them more resistant to chemotherapy and other treatments. By inhibiting the activity of CD48 antigen, researchers can

Protein Name: CD48 Molecule

Functions: Glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that interacts via its N-terminal immunoglobulin domain with cell surface receptors including 2B4/CD244 or CD2 to regulate immune cell function and activation (PubMed:27249817, PubMed:12007789). Participates in T-cell signaling transduction by associating with CD2 and efficiently bringing the Src family protein kinase LCK and LAT to the TCR/CD3 complex (PubMed:19494291). In turn, promotes LCK phosphorylation and subsequent activation (PubMed:12007789). Induces the phosphorylation of the cytoplasmic immunoreceptortyrosine switch motifs (ITSMs) of CD244 initiating a series of signaling events that leads to the generation of the immunological synapse and the directed release of cytolytic granules containing perforin and granzymes by T-lymphocytes and NK-cells (PubMed:9841922, PubMed:27249817)

The "CD48 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD48 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23